Health & Pharmaceutical Landscape of New Zealand | March 2022

Page 91

2. Bulk drug parks scheme •

The US$ 400 million scheme emphasises on the promotion of drug parks for the manufacturing of bulk drugs.

The scheme will reduce import dependence along with decreasing cost of bulk drugs in the country.

3. State government schemes •

States have specific policies for the promotion of life sciences industry. For instance, the Government of Telangana had implemented the Life Sciences Policy (2015-2020), which significantly contributed to the development of biotechnology and pharma ecosystem in the state. Telangana’s Genome valley, in Hyderabad, now contributes to ~33% of the supply of vaccines to the globe.

Similarly, the Government of Gujarat has published the Biotechnology Policy (20222027) to impart impetus to the burgeoning biotechnology sector.

These policies aim to provide specific incentives for promotion of the industry in the state. For instance, incentives pertaining to land, capital, and power are given by the state governments – further boosting manufacturing capabilities of the Indian pharmaceuticals industry.

Support provided by Make in India / Invest India team. Project Development Cells (PDCs) have been constituted in 29 ministries and departments of the Government of India. Invest India is mandated by the Government of India to handhold investors in their investment journey in India. A PDC has been established between Department of Pharmaceuticals and Invest India. The PDC works to address grievances related to the implementation of the PLI scheme and any other investment plans, among various other initiatives listed below: •

Facilitate investors: PDCs help investors in getting regulatory/land approvals or address grievances pertaining to different schemes launched by the Department of Pharmaceuticals, Government of India.

Develop policy initiatives: In close discussion with the Department of Pharmaceuticals and industry leaders, regular webinars and brainstorming sessions are conducted to further streamline the investment landscape in the pharma sector.

Content Courtesy: Invest India Team

Healthcare & Pharmaceutical Landscape of NZ

91


Turn static files into dynamic content formats.

Create a flipbook

Articles inside

Support provided by Make in India / Invest India team

1min
page 91

Are there any incentives?

1min
page 90

What is the policy framework for foreign pharma companies to manufacture / collaborate with Indian companies?

0
page 89

List of important companies in New Zealand’s pharma sector

2min
pages 83-86

Media Extract: BURDEN OF PROOF IS ON MEDSAFE TO JUSTIFY ITS EXISTENCE

2min
pages 64-65

A Decade of Modern Medicines: An International Comparison 2011 – 2020

2min
page 56

Understanding the Supplemented Food Standards

0
page 60

Industry Perspective

2min
page 61

Other sources of information

0
page 62

Vaccines: PHARMAC’s role

2min
pages 53-54

Hospital Medical Devices

1min
page 52

Myths & FAQs on tendering process

0
page 51

How does the annual tender work?

3min
pages 48-50

From application to funded medicine: PHARMAC's process

2min
pages 45-46

Procurement & tendering process

1min
page 47

How PHARMAC gets clinical advice into their decision-making

1min
page 44

How new medicines get funded ?

3min
pages 40-41

How the health priorities affect PHARMAC's work

1min
page 42

Medical Devices

2min
pages 37-38

What do I need to do to sell my medicine in New Zealand?

2min
pages 35-36

How new medicines get funded by PHARMAC

0
page 24

Main agencies involved in managing the sector

4min
pages 9-11

Introductory Regulatory Guidance

3min
pages 33-34

Who is a Sponsor?

4min
pages 19-21

Putting the Factors to work

2min
pages 25-26

Foreword

1min
page 5

Medsafe's Evaluation and Approval Process

5min
pages 29-32

Foreword

2min
pages 6-7
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.